Lab-on-a-Chip: The Future of Cervical Pre-Cancer Diagnostics
H Keegan, T Baier, T Hansen-Hagge, F Karlsen, A Gullicksen, P Gronn, L Solli, M Mielnik, L Furuberg, P Koltay, L Riegger, N Bolger, JJ O'Leary, CM Martin. University of Dublin, Trinity College, Dublin 2, Ireland; Institut fur Mikrotechnik Mainz GmbH, Mainz, Germany; Norchip AS, Klokkarstua, Norway; SINTEF Microsystems and Nanotechnology, Oslo, Norway; Biofluidix GmbH, Freiburg, Germany; Coombe Women and Infants University Hospital, Dublin, Ireland
Background: Cervical cancer development is directly linked to persistent infection with high-risk HPV and the expression of E6/E7 ongogenic mRNA transcripts. The aim of this project is to develop an automated point-of-care platform for sample preparation, nucleic acid extraction, amplification and detection of oncogenic HPV types. This study forms part of an EU 6th Framework funded project “Microactive” and is also supported by the CERVIVA Consortium, funded by the Health Research Board, Ireland.
Design: The point of care system consists of two biochips, one for sample preparation and the other for HPV detection, each involving a disposable chip and a reusable instrument. The HPV detection device allows on-chip parallel NASBA amplification and fluorescent detection of up to 16 different HPV mRNA types in 8 parallel microfluidic channels. The system has been tested on liquid based cervical cytology specimens from women with persistent oncogenic HPV infection.
Results: Studies on CaSki and HeLa cervical cancer cell lines showed that HPV mRNA could be detected down to the order of 5 cervical cells. Proof of concept experiments on clinical specimens (n=6) indicated that HPV mRNA was successfully extracted and amplified from clinical specimen using this point of care lab on a chip approach.
Conclusions: This project is the first to describe a complete lab on a chip system which successfully extracts nucleic acids sample preparation and detection on clinical specimens, ie cervical smears. The Microactive lab-on-a-chip system may be optimised further and adapted for a wide range of clinical tests involving biomarker detection.
Tuesday, March 23, 2010 11:30 AM
Platform Session: Section F, Tuesday Morning